Studies on a new analeptic agent, centphenaquin (11-N4-phenylpiperazine)-7,8,9,10-tetrahydro-6H-cyclohepta[b]qui noline dihydrochloride): Part II. Other pharmacological effects.
Patnaik
G K
GK
Dhawan
B N
BN
D000698:Analgesia; D000818:Animals; D001066:Appetite / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D010424:Pentobarbital / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012110:Reserpine / Q000037:antagonists & inhibitors; D009435:Synaptic Transmission / Q000187:drug effects; D014590:Uterine Contraction / Q000187:drug effects
D000697:Central Nervous System Stimulants; D010879:Piperazines; D012110:Reserpine; C047582:centphenaquin; D010424:Pentobarbital